Ocular Toxicities Associated with ADCs and Other Cancer Therapies: Part 2 — An Interview with Dr Neel Pasricha on Adverse Event Management
Research To Practice | Oncology Videos · Dr. Neil Love
September 16, 202554m 23s
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Featuring an interview with Dr Neel Pasricha, including the following topics:
- Anatomy and physiology of the cornea; intersection of ophthalmology and oncology for patients receiving antibody-drug conjugates (ADCs) (0:00)
- Association of corneal toxicities with ADCs (4:56)
- Dose and schedule modifications to mitigate ocular toxicities associated with belantamab mafodotin and other ADCs (9:02)
- Spectrum and severity of corneal toxicities associated with datopotamab deruxtecan (14:44)
- Role of optometrists and ophthalmologists in screening for and management of ocular toxicities (17:55)
- Other ocular toxicities associated with cancer therapies (24:26)
- Prevention and management of corneal toxicity (33:58)
- Preexisting ophthalmic conditions as potential risk factors for development of ocular toxicities with ADCs (43:39)
- General clinical pearls on the management of ocular toxicities with cancer therapies (48:04)